Mindray Medical Injects CN¥2 Billion into Wuhan Subsidiary Amid Hong Kong IPO Filing

According to Qichacha news on December 8, 2025,Mindray Scientific undergoes major changes in capital operations and corporate management, completing Series A financing, with Mindray taking over as the controlling shareholder., becoming the largest shareholder of Wuhan Mindray at one stroke.

At the same time, the registered capital of Wuhan Mindray Scientific Co., Ltd. has significantly increased from 300 million yuan to 2.3 billion yuan, injecting strong momentum for its subsequent development. In addition, the legal representative of the company has been changed from Shi Peng to Han Le, indicating thatWuhan Mindray Scientific Co., Ltd.'s Management Team to Undergo Major Adjustment`, the new leadership team is expected to lead the company into a new stage of development.`

Wuhan Mindray ScientificHeadquartered in Wuhan, asA technology enterprise focusing on the development and research of orthopedic consumables and medical devices, with deep technical accumulation and professional strength in the industry. Behind this equity and management change lies Mindray's deep resource integration strategy in the Wuhan area.

Previously, Wuhan Mindray Bio-Medical Technology Co., Ltd., as the second global headquarters base of Mindray, invested over 4.5 billion yuan. It was officially deregistered on December 3, but in fact, it had already merged with Wuhan Mindray Scientific Co., Ltd. Moving forward, Mindray will conduct operations through Wuhan Mindray Scientific Co., Ltd. as the main entity, concentrating advantageous resources to enhance overall operational efficiency and market competitiveness.

Mindray's Wuhan Base, as its global second headquarters base, has attracted significant attention since its planning and construction began.The base has a total investment of 4.5 billion yuan, with a total construction area of approximately 530,000 square meters, covering two core sub-projects: the Wuhan Research Institute and the production and manufacturing base.

Wuhan Research Institute is positioned as an ultra-large R&D center, focusing on the biomedical engineering R&D field. It conducts multiple key research projects, including the development of biological raw materials and reagents, surgical equipment R&D, and health technology R&D, providing solid support for Mindray's technological innovation and product upgrades. The Wuhan production and manufacturing base is mainly responsible for the production, manufacturing, and business services of medical devices and biological raw materials, ensuring the efficient transformation of products from R&D to mass production.